GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vivesto AB (OSTO:VIVE) » Definitions » Cyclically Adjusted PS Ratio

Vivesto AB (OSTO:VIVE) Cyclically Adjusted PS Ratio : (As of Jun. 03, 2025)


View and export this data going back to 2005. Start your Free Trial

What is Vivesto AB Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Vivesto AB Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Vivesto AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivesto AB Cyclically Adjusted PS Ratio Chart

Vivesto AB Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 59.54 18.21 - - -

Vivesto AB Quarterly Data
Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vivesto AB's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Vivesto AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivesto AB's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vivesto AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vivesto AB's Cyclically Adjusted PS Ratio falls into.


;
;

Vivesto AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Vivesto AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Vivesto AB's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0/132.8245*132.8245
=0.000

Current CPI (Mar. 2025) = 132.8245.

Vivesto AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201504 0.000 99.941 0.000
201507 0.001 100.027 0.001
201510 0.000 100.301 0.000
201601 0.036 99.931 0.048
201604 0.000 100.732 0.000
201607 0.000 101.080 0.000
201610 0.000 101.485 0.000
201701 0.000 101.326 0.000
201704 0.000 102.615 0.000
201707 0.000 103.301 0.000
201710 0.006 103.202 0.008
201801 0.002 102.925 0.003
201804 0.003 104.390 0.004
201807 0.000 105.420 0.000
201810 0.001 105.545 0.001
201901 0.005 104.855 0.006
201904 0.001 106.627 0.001
201907 0.001 107.166 0.001
201910 0.001 107.243 0.001
202001 0.000 106.215 0.000
202004 0.449 106.240 0.561
202007 0.000 107.731 0.000
202010 0.000 107.539 0.000
202103 0.000 108.360 0.000
202106 0.009 108.928 0.011
202109 0.027 110.338 0.033
202112 0.021 112.486 0.025
202203 0.000 114.825 0.000
202206 0.000 118.384 0.000
202209 0.002 122.296 0.002
202212 0.000 126.365 0.000
202303 0.000 127.042 0.000
202306 0.000 129.407 0.000
202309 0.000 130.224 0.000
202312 0.000 131.912 0.000
202403 0.000 132.205 0.000
202406 0.000 132.716 0.000
202409 0.000 132.304 0.000
202412 0.000 132.987 0.000
202503 0.000 132.825 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vivesto AB  (OSTO:VIVE) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Vivesto AB Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Vivesto AB's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivesto AB Business Description

Industry
Traded in Other Exchanges
Address
Gustav III:s Boulevard 46, 5th Floor, Solna, SWE, SE-169 73
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.